Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)-

Request For Quotation

Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)- manufacturers

  • MAT2A-IN-10
  • MAT2A-IN-10 pictures
  • $2780.00
  • 2026-05-11
  • CAS:2924825-23-8
  • Purity:
  • Supply Ability: 10g
Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)- Basic information
Product Name:Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)-
Synonyms:Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)-;MAT2A-IN-10
CAS:2924825-23-8
MF:C27H24F2N6O4
MW:534.52
EINECS:
Product Categories:
Mol File:2924825-23-8.mol
Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)- Structure
Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)- Chemical Properties
Boiling point 739.9±70.0 °C(Predicted)
density 1.48±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)
pka7.42±0.20(Predicted)
Safety Information
MSDS Information
Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)- Usage And Synthesis
UsesMAT2A-IN-10 (Compound 28) is an orally active MAT2A inhibitor with an IC50 of 26 nM. MAT2A-IN-10 can be used for the research of cancer[1].
in vivo

MAT2A-IN-10 (Compound 28; p.o.; once daily for 6 days) results in tumor regression in the HCT-116 (MTAP-/-) xenograft tumor model in BALB/c mice[1].

Animal Model:BALB/c mice, HCT-116(MTAP-/-) xenograft mouse tumor model[1]
Dosage:50 mg/kg
Administration:PO, once daily for 6 days
Result:Resulted in tumor regression. Induced a continuous decrease in tumor volume after day 6, and the tumor regression reached -52% at the end of treatment (day 18).
Animal Model:Male ICR Mice[1]
Dosage:10 mg/kg
Administration:Oral (Pharmacokinetic Analysis)
Result:Pharmacokinetic Properties of MAT2A-IN-10 (Compound 28) in Male ICR Mice (n = 3)a
routedose [mg/kg]Tmax [h]T1/2 [h]MRT [h]Cmax [ng/mL]AUC [ngh/mL]
po100.672.984.71673341192

aTmax, time for maximum plasma concentration; T1/2, elimination half-life; MRT, mean residue time; Cmax, maximum plasma concentration; AUC, area under drug time curve.
References[1] Zhang S, et al. Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability. J Med Chem. 2023 Apr 13;66(7):4849-4867. DOI:10.1021/acs.jmedchem.2c02006
Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)- Preparation Products And Raw materials
Tag:Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)-(2924825-23-8) Related Product Information
Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[4-(difluoromethoxy)phenyl]-7-ethoxy-3-(1,2,3,4-tetrahydro-2-methylpyrazino[1,2-a]benzimidazol-7-yl)- Pyridine, 3-(1H-1,2,3-triazol-4-yl)- (9CI) 7(8H)-Pteridinone, 8-[4-(difluoromethoxy)phenyl]-2-ethoxy-6-[2-(1-hydroxy-1-methylethyl)-1-methyl-1H-benzimidazol-6-yl]- AGI-24512 Pyrido[4,3-d]pyrimidin-7(6H)-one, 8-(4-bromophenyl)-6-(4-methoxyphenyl)-2-[(2,2,2-trifluoroethyl)amino]- PF-9366